RxSight, Inc. (RXST) Initiated at Market Perform as Firm Seeks Sales Reacceleration

We recently published an article titled 10 Best Long Term Healthcare Stocks to Buy.

On January 30, William Blair initiated coverage of RxSight, Inc. (NASDAQ:RXST) with a Market Perform rating and no price target. The firm cited stalled sales growth in 2025 following strong adoption from early users between 2021 and 2024, noting that evidence of a sustained commercial reacceleration is needed despite the stock trading at a discount to peers.

During its third-quarter 2025 earnings call, RxSight, Inc. (NASDAQ:RXST) narrowed full-year revenue guidance to a range of $125 million to $130 million, compared with prior guidance of $120 million to $130 million. The company highlighted continued progress in its international rollout, particularly in Asia and Europe, supported by regulatory approvals and commercial infrastructure investments. Management indicated that these regions are expected to contribute incrementally to revenue over a multiyear period as adoption increases.

RxSight, Inc. (NASDAQ:RXST) was founded in 1997 and is based in Aliso Viejo, California. The company develops adjustable intraocular lenses used in cataract surgery, allowing post-operative vision correction.

While we acknowledge the potential of RXST as a long term investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 8 Up and Coming Streaming Companies and Services and 9 High Growth Canadian Stocks to Buy

Disclosure: None.